Abstract:Cellular senescence is a state of permanent cell-cycle arrest. Early in life, senescence has a physiologic role in tumor suppression and wound healing. However, gradually, as these senescent cells accumulate over the lifespan of an organism, they contribute to inflammation and the progression of age-related diseases, including neurodegeneration. Targeting senescent cells using a class of drugs known as "senolytics" holds great promise for the management of Alzheimer's and Parkinson's disease. Already, several senolytic compounds have been shown to ameliorate cognitive deficits across several preclinical models of neurodegeneration. Most of these senolytics (e.g., dasatinib) are repurposed clinical or experimental anticancer drugs, which trigger apoptosis of senescent cells by interfering with pro-survival pathways. However, outside of their senolytic function, many first-generation senolytics also have other less appreciated neuroprotective effects, such as potent antioxidant and anti-inflammatory activity. In addition, some senolytic drugs may also have negative dose-limiting toxicities, including thrombocytopenia. In this review, we discuss the various biologic pathways targeted by the leading senolytic drugs, namely dasatinib, quercetin, fisetin, and navitoclax. We further evaluate the clinical transability of these compounds for neurodegeneration, assessing their adverse effects, pharmacokinetic properties, and chemical structure. SIGNIFICANCE STATEMENT Currently, there are no effective disease-modifying treatments for the most prevalent neurodegenerative disorders, including Alzheimer's and Parkinson's disease. Some of the drugs currently available for treating these diseases are associated with unwanted side-effects and/or become less efficacious with time. Therefore, researchers have begun to explore new innovative treatments for these belligerent diseases, including senolytic drugs. These agents lead to the apoptosis of senescent cells thereby preventing their deleterious role in neurodegeneration.

Revisiting sensitivity of senescent cells to BH3 mimetics

Targeted clearance of senescent cells using an antibody-drug conjugate against a specific membrane marker

Abstract PR013: BH3 profiling of senescent cancer cells to identify mechanisms of resistance to ABT-263

Cellular senescence and senolytics: the path to the clinic

Senescent Cell Depletion Through Targeting BCL-Family Proteins and Mitochondria

Insights into targeting cellular senescence with senolytic therapy: The journey from preclinical trials to clinical practice

BH3-mimetics: recent developments in cancer therapy

HRK downregulation and augmented BCL-xL binding to BAK confer apoptotic protection to therapy-induced senescent melanoma cells

Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics

BID- and BAX-mediated mitochondrial pathway dominates A-1331852-induced apoptosis in senescent A549 cells

New agents that target senescent cells: the flavone, fisetin, and the BCL-XL inhibitors, A1331852 and A1155463

Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice

Cell senescence in neuropathology: A focus on neurodegeneration and tumours

Exploiting senescence for the treatment of cancer

Therapeutic targeting of senescent cells in the CNS

The Achilles’ heel of senescent cells: from transcriptome to senolytic drugs

Pharmacological Targeting of Senescence with Senolytics as a New Therapeutic Strategy for Neurodegeneration

Targeting Cellular Senescence in Aging and Age-Related Diseases: Challenges, Considerations, and the Emerging Role of Senolytic and Senomorphic Therapies

BH3 Mimetic Peptides: An Effective Strategy to Complement Anticancer Therapy

Role of immune cells in the removal of deleterious senescent cells

Bcl-xL as a Modulator of Senescence and Aging